Practice
Featured experience
Comcast spinoff of select cable television networks
We are advising Comcast on the transaction
Durational Capital Management strategic investment in Garage Beer
We are advising Durational Capital Management on the transaction
Arcos Dorados renewal of long-term master franchise agreement with McDonald’s
We advised Arcos Dorados on the transaction
GSK strategic alliance with Vesalius Therapeutics
We advised GSK on the transaction
Inventiva $108 million U.S. IPO and Nasdaq listing
Davis Polk advised the representatives of the underwriters in connection with an initial public offering of Inventiva S…
Royalty Pharma $2.5 billion IPO
Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $2.5 billion initial public offering…
Generation Bio $230 million IPO
Davis Polk advised the representatives of the underwriters in connection with the $230 million initial public offering…
Novo Nordisk $725 million acquisition of Corvidia Therapeutics
Davis Polk is advising Novo Nordisk A/S on its acquisition of Corvidia Therapeutics Inc. for an upfront payment of $725…
Legend Biotech $487 million IPO
Davis Polk advised the underwriters in connection with the $487 million SEC-registered initial public offering by Legend…
Warner Music Group $1.925 billion IPO
Davis Polk advised the representatives of the several underwriters, in connection with the $1.925 billion initial…
ADC Therapeutics $267 million IPO
Davis Polk advised ADC Therapeutics SA on its SEC-registered initial public offering of 14,082,475 common shares, which…
Ayala Pharmaceuticals $55 million IPO
Davis Polk advised the underwriters in connection with the $55 million initial public offering of 3,666,667 shares of…
Dean Foods sale of assets to six acquirers, including Dairy Farmers of America
Davis Polk advised Dean Foods Company on the sale of substantially all of Dean Foods’s assets and business operations…
Revlon BrandCo $815 million financing
We are advising Revlon’s BrandCo lenders